The biopharma buffer market consists of various buffers that maintain the pH of biological fluids within a specific range to support chemical reactions in bioprocesses. Buffers help maintain stable environmental conditions and optimal pH levels required by biopharmaceutical manufacturing processes. They support various downstream processes such as chromatography, filtration, and formulation during drug production. The global Biopharma Buffer Market is estimated to be valued at US$3.68 billion in 2024 and is expected to exhibit a CAGR of 11% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Opportunity:
The growing demand for biologics driven by increasing awareness regarding innovation in biotherapeutics presents a lucrative opportunity for the biopharma buffer market players. As per estimates, the global biologics market was valued at US$ 267 billion in 2019 and is projected to reach US$ 545 billion by 2027, growing at a CAGR of 9.4%. The exponential growth of the biologics segment has increased outsourcing activities in biologics manufacturing globally. Rapid expansion of contract manufacturing organizations has augmented the requirement for downstream processing equipment and solutions like buffers. CMOs rely heavily on buffers to maintain optimal conditions for purification and formulation processes of biologics. Thus, the rising trend of outsourcing in the biopharma industry presents lucrative opportunities for buffer manufacturers to strengthen their presence in the high-growth biologics market.
Porter's Analysis
Threat of new entrants: The threat of new entrants is moderate as the biopharma buffer market requires huge investment and infrastructure for R&D and manufacturing. However, patent expiries provide opportunities for new players.
Bargaining power of buyers: The bargaining power of buyers is high due to the presence of various buffer solution providers and easy switchability between suppliers. Price competition is intense.
Bargaining power of suppliers: The bargaining power of suppliers is moderate as there are limited suppliers of raw materials for buffer solutions and industry consolidation has increased supplier bargaining power.
Threat of new substitutes: The threat of new substitutes is low as buffer solutions are essential for biopharma research and development activities. No cost-effective substitutes are available.
Competitive rivalry: Competition in the market is high and industry players continuously focus on new product innovations, expansions, and mergers and acquisitions to gain market share.
SWOT Analysis
Strengths: Biopharma buffer solutions have wide applications in drug development, clinical research, and manufacturing. Leading players have strong R&D capabilities and global presence.
Weaknesses: High setup and maintenance costs of buffer preparation facilities. Dependence on overseas suppliers for raw materials increases supply chain vulnerabilities.
Opportunities: Growth in biopharmaceutical industry and outsourcing of bioproduction activities to developing markets provide opportunities for buffer suppliers.
Threats: Stringent regulatory environment increases compliance costs. Price erosion due to low differentiation between products.
Key Takeaways
The Global Biopharma Buffer Market Size is expected to witness high growth over the forecast period of 2023 to 2030 driven by increasing biologics production and rising R&D investments. The market size for 2024 is projected to reach US$ 3.68 billion registering a CAGR of 11%.
Regional analysis: North America dominates the global biopharma buffer market accounting for over 35% of the global market share in 2024. This is attributed to presence of major biopharmaceutical companies and stringent regulatory guidelines in the region regarding buffer quality. Asia Pacific is expected to be the fastest growing region during the forecast period growing at a CAGR of around 13% owing to increasing outsourcing of bioproduction activities to China and India.
Key players operating in the biopharma buffer market are Avantor Performance Materials, Inc., SRL Diagnostics Private Limited, Bio-Rad Laboratories, Inc., Lonza Group AG, Merck KGaA, Thermo Fisher Scientific Inc., and XZL BIO-TECHNOLOGY CO., LTD. Leading players focus on new geographical expansions and introduction of innovative products to strengthen their market position.
Get More Insights Here
Comments
0 comment